Pentosan polysulfate sodium is under clinical development by Paradigm Biopharmaceuticals and currently in Phase II for Osteoarthritis. According to GlobalData, Phase II drugs for Osteoarthritis have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pentosan polysulfate sodium’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pentosan polysulfate sodium overview

Pentosan polysulfate sodium (PPS) is under development for the treatment of osteoarthritis of the knee, osteoarthritis pain, mucopolysaccharidosis I (MPS I), MPS VI, bone marrow edema, heart failure, allergic asthma, seasonal allergic rhinitis, RRV (Ross River virus), coronavirus disease 2019 (COVID-19) associated acute respiratory distress syndrome and CHIKV (chikungunya virus) induced arthritis and arthralgia (joint pain). It is administered by subcutaneous, intramuscular route and intra-nasal route. It is a semi synthetic polysaccharide developed based on repurposing strategy. It acts by targeting ADAMTS-5, Collagenase 3 and Stromelysin-1.

Paradigm Biopharmaceuticals overview

Paradigm Biopharmaceuticals (Paradigm Biopharma), is biopharmaceutical company. The company engaged in the research and development of therapeutic products for human use. It offers pentosan polysulphate sodium (PPS) drugs for new orthopaedic and respiratory applications. Paradigm Biopharma offers drugs in the injectable and tablet forms for bone marrow edema, respiratory disease, alphaviral arthritis, orthopaedic, alphavirus, and respiratory diseases. The company’s other indications include treating the allergic inflammatory response in allergic rhinitis (AR). It also conducts a phase 2b clinical trial to investigate PPS in subjects with Bone Marrow Lesions (BMLs) and osteoarthritis (OA). Paradigm Biopharma is headquartered in Melbourne, Victoria, Australia.

For a complete picture of Pentosan polysulfate sodium’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.